Related Experiment Video

Updated: Jan 26, 2026

Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope
07:42

Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope

Published on: November 29, 2011

12.8K

Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come

Craig Furman1, Ming-Hong Hao2, Sudeep Prajapati1

  • 1H3 Biomedicine, Inc., Cambridge, Massachusetts.

Cancer Research
|April 7, 2019
PubMed

Insights

A novel estrogen receptor alpha (ERα) antagonist, H3B-5942, offers enhanced potency by targeting a unique cysteine. This covalent approach may overcome resistance in breast cancer therapies, reducing the risk of escape mutations.

Area of Science:

  • Oncology
  • Endocrinology
  • Medicinal Chemistry

Background:

  • Estrogen receptor alpha (ERα) antagonists like tamoxifen are vital in breast cancer treatment.
  • Therapeutic resistance to ERα antagonists is a significant clinical challenge.
  • Many resistant tumors still rely on ERα signaling, necessitating improved therapeutic strategies.

Purpose of the Study:

  • To introduce a novel ERα antagonist, H3B-5942, designed for enhanced potency.
  • To explore the covalent targeting mechanism of H3B-5942 against a unique cysteine in ERα.
  • To discuss future directions for improving ERα antagonist therapies and mitigating resistance.

Main Methods:

  • Design and development of a novel ERα antagonist (H3B-5942).
  • Investigation of covalent targeting of a unique cysteine residue in the ERα ligand-binding domain.
  • Review of existing literature on ERα antagonist resistance mechanisms.

Main Results:

  • H3B-5942 demonstrates enhanced potency compared to existing ERα antagonists.
  • The covalent mechanism targets a specific cysteine, offering a novel approach to ERα inhibition.
  • The development of H3B-5942 addresses the clinical need for overcoming resistance.

Conclusions:

  • H3B-5942 represents a promising new therapeutic candidate for ERα-positive breast cancers.
  • Covalent targeting of ERα offers a strategy to overcome common resistance mutations.
  • Further research into H3B-5942 and similar agents could significantly improve patient outcomes.

More Related Videos

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.3K
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

6.8K

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
Covalent Bonds01:29

Covalent Bonds

Overview
160.9K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Network Covalent Solids02:18

Network Covalent Solids

Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.3K